Short-term supplementation of celecoxib-shifted butyrate production on a simulated model of the gut microbial ecosystem and ameliorated in vitro inflammation

Abstract

Celecoxib has been effective in the prevention and treatment of chronic inflammatory disorders through inhibition of altered cyclooxygenase-2 (COX-2) pathways. Despite the benefits, continuous administration may increase risk of cardiovascular events. Understanding microbiome-drug-host interactions is fundamental for improving drug disposition and safety responses of colontargeted formulations, but little information is available on the bidirectional interaction between individual microbiomes and celecoxib. Here, we conducted in vitro batch incubations of human faecal microbiota to obtain a mechanistic proof-of-concept of the short-term impact of celecoxib on activity and composition of colon bacterial communities. Celecoxib-exposed microbiota shifted metabolic activity and community composition, whereas total transcriptionally active bacterial population was not significantly changed. Butyrate production decreased by 50% in a donor-dependent manner, suggesting that celecoxib impacts in vitro fermentation. Microbiota-derived acetate has been associated with inhibition of cancer markers and our results suggest uptake of acetate for bacterial functions when celecoxib was supplied, which potentially favoured bacterial competition for acetyl-CoA. We further assessed whether colon microbiota modulates anti-inflammatory efficacy of celecoxib using a simplified inflammation model, and a novel in vitro simulation of the enterohepatic metabolism. Celecoxib was responsible for only 5% of the variance in bacterial community composition but celecoxib-exposed microbiota preserved barrier function and decreased concentrations of IL-8 and CXCL16 in a donor-dependent manner in our two models simulating gut inflammatory milieu. Our results suggest that celecoxib-microbiome-host interactions may not only elicit adaptations in community composition but also in microbiota functionality, and these may need to be considered for guaranteeing efficient COX-2 inhibition.npj Biofilms and Microbiomes (2020) 6:9 ; https://doi.

In-Depth Observation on the Microbial and Fungal Community Structure of Four Contrasting Tomato Cultivation Systems in Soil Based and Soilless Culture Systems

“…High-throughput amplicon sequencing of the V3 -V4 hypervariable region (Klindworth et al, 2012) was performed with the Illumina MiSeq platform (LGC Genomics GmbH, Berlin, Germany) and the following primers were used 338f and the 518 r (Øvreås et al, 1997). Bioinformatics and data pre-processing followed a protocol developed in-house (El Hage et al, 2019;Grunert et al, 2019;Hernandez-Sanabria et al, 2020). A generalized linear mixed model was employed to compute the effect of tomato cultivating system and time and the interactions between "tomato cultivating system" and time on each individual genus (El Hage et al, 2019;Grunert et al, 2019;Hernandez-Sanabria et al, 2020).…”

“…Bioinformatics and data pre-processing followed a protocol developed in-house (El Hage et al, 2019;Grunert et al, 2019;Hernandez-Sanabria et al, 2020). A generalized linear mixed model was employed to compute the effect of tomato cultivating system and time and the interactions between "tomato cultivating system" and time on each individual genus (El Hage et al, 2019;Grunert et al, 2019;Hernandez-Sanabria et al, 2020). Differences among library size sample were accounted for with the offset option in proc GLIMMIX in SAS (Paschold et al, 2012;El Hage et al, 2019).…”

“…In addition, MFA was applied to assess the correlations between the chemical and microbiological variables based on the PLFA analysis and bacterial abundance detected in the four tomato cultivating systems. R was used (Grunert et al, 2019;Hernandez-Sanabria et al, 2020) to compute the function MFA from the FactoMineR package (Lê et al, 2008).…”

NSAID–Gut Microbiota Interactions

“…In this small study, the inter-individual variability in response to celecoxib could have masked the effect of this drug on the diversity of the gut microbiota. On this note, a recent study reported that without altering the composition of the microbiota, celecoxib can decrease microbial butyrate production in a human intestinal microbiota ecosystem model and also diminish markers of inflammation like IL-8 and CXCL16 in intestinal cells in vitro (Hernandez-Sanabria et al, 2020).…”

Nonsteroidal Anti-Inflammatory Drugs as Therapeutic Allies of the Gut Microbiome on Chronic Inflammation

“…This implies that the relation between plasma concentrations and efficacy has a low predictive value. For this reason, investigating microbiome-drug-host interactions towards improving ADME and safety responses of intestinal targets is fundamental [12].…”